AZN
AstraZeneca PLC
Price Chart
Latest Quote
$168.70
-0.59 (-0.35%)
Current Price
| Previous Close | $169.29 |
| Open | $168.15 |
| Day High | $170.31 |
| Day Low | $167.16 |
| Volume | 508,376 |
Stock Information
| Quarterly Dividend / Yield | $3.16 / 1.87% |
| Shares Outstanding | 1.55B |
| Quarterly Dividend Yield | 1.87% |
| Quarterly Dividend | $3.16 |
| Total Debt | $34.03B |
| Cash Equivalents | $7.67B |
| Revenue | $60.44B |
| Net Income | $10.39B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $263.08B |
| P/E Ratio | 25.55 |
| EPS (TTM) | $6.64 |
| Exchange | NYQ |
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $168.90 | 1,980,800 |
| 2026-07-16 | $169.29 | 3,018,300 |
| 2026-07-15 | $168.37 | 2,938,200 |
| 2026-07-14 | $164.50 | 3,605,500 |
| 2026-07-13 | $169.47 | 4,666,100 |
| 2026-07-10 | $171.61 | 3,596,900 |
| 2026-07-09 | $178.49 | 6,649,000 |
| 2026-07-08 | $189.28 | 1,967,800 |
| 2026-07-07 | $193.12 | 2,130,000 |
| 2026-07-06 | $190.16 | 1,872,000 |
| 2026-07-02 | $195.15 | 2,379,500 |
| 2026-07-01 | $183.86 | 2,115,500 |
| 2026-06-30 | $189.62 | 2,598,700 |
| 2026-06-29 | $190.95 | 1,644,300 |
| 2026-06-26 | $188.41 | 3,235,300 |
| 2026-06-25 | $185.68 | 1,826,200 |
| 2026-06-24 | $183.02 | 2,377,700 |
| 2026-06-23 | $181.02 | 1,503,700 |
| 2026-06-22 | $176.43 | 1,489,600 |
| 2026-06-18 | $174.93 | 1,667,000 |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
đ° Latest News
Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?
Simply Wall St. âĸ 2026-07-18T00:17:23Z
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
24/7 Wall St. âĸ 2026-07-17T15:05:33Z
MSD wins FDA approval for cholesterol pill to help plug Keytruda void
Pharmaceutical Technology âĸ 2026-07-17T10:31:24Z
Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
Barrons.com âĸ 2026-07-16T19:42:00Z
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Zacks âĸ 2026-07-16T17:05:00Z
Attractive Growth Profile Positions AstraZeneca PLC (AZN) as Opportunity
Insider Monkey âĸ 2026-07-16T13:14:24Z
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
Zacks âĸ 2026-07-15T16:04:00Z
AstraZeneca (LSE:AZN) Secures Zegfrovy In $1.5 Billion Lung Cancer Licensing Deal
Simply Wall St. âĸ 2026-07-15T13:12:04Z
Eli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Million
Bloomberg âĸ 2026-07-15T10:00:00ZJ&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
BioPharma Dive âĸ 2026-07-15T09:18:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $10,633,000,000 | $10,207,000,000 | $8,268,000,000 | $12,391,000,000 |
| Cost Of Revenue | $10,633,000,000 | $10,207,000,000 | $8,268,000,000 | $12,391,000,000 |
| Total Revenue | $58,739,000,000 | $54,073,000,000 | $45,811,000,000 | $44,351,000,000 |
| Operating Revenue | $58,739,000,000 | $54,073,000,000 | $45,811,000,000 | $44,351,000,000 |
| Expenses | ||||
| Interest Expense | $1,614,000,000 | $1,682,000,000 | $1,589,000,000 | $1,330,000,000 |
| Total Expenses | $45,412,000,000 | $43,822,000,000 | $37,089,000,000 | $39,839,000,000 |
| Rent Expense Supplemental | $452,000,000 | $377,000,000 | $301,000,000 | $268,000,000 |
| Net Non Operating Interest Income Expense | $-1,254,000,000 | $-1,337,000,000 | $-1,288,000,000 | $-1,249,000,000 |
| Interest Expense Non Operating | $1,614,000,000 | $1,682,000,000 | $1,589,000,000 | $1,330,000,000 |
| Operating Expense | $34,779,000,000 | $33,615,000,000 | $28,821,000,000 | $27,448,000,000 |
| Other Operating Expenses | $134,000,000 | $121,000,000 | $164,000,000 | $200,000,000 |
| Selling And Marketing Expense | $579,000,000 | $555,000,000 | $539,000,000 | $536,000,000 |
| General And Administrative Expense | $20,195,000,000 | $19,669,000,000 | $17,683,000,000 | $17,448,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $10,225,000,000 | $7,035,000,000 | $5,955,000,000 | $3,288,000,000 |
| Net Interest Income | $-1,254,000,000 | $-1,337,000,000 | $-1,288,000,000 | $-1,249,000,000 |
| Interest Income | $360,000,000 | $345,000,000 | $301,000,000 | $81,000,000 |
| Normalized Income | $9,924,060,000 | $7,158,952,710 | $6,377,514,712 | $3,888,210,000 |
| Net Income From Continuing And Discontinued Operation | $10,225,000,000 | $7,035,000,000 | $5,955,000,000 | $3,288,000,000 |
| Total Operating Income As Reported | $13,743,000,000 | $10,003,000,000 | $8,193,000,000 | $3,757,000,000 |
| Net Income Common Stockholders | $10,225,000,000 | $7,035,000,000 | $5,955,000,000 | $3,288,000,000 |
| Net Income | $10,225,000,000 | $7,035,000,000 | $5,955,000,000 | $3,288,000,000 |
| Net Income Including Noncontrolling Interests | $10,233,000,000 | $7,041,000,000 | $5,961,000,000 | $3,293,000,000 |
| Net Income Continuous Operations | $10,233,000,000 | $7,041,000,000 | $5,961,000,000 | $3,293,000,000 |
| Pretax Income | $12,402,000,000 | $8,691,000,000 | $6,899,000,000 | $2,501,000,000 |
| Special Income Charges | $416,000,000 | $-248,000,000 | $-529,000,000 | $-755,000,000 |
| Interest Income Non Operating | $360,000,000 | $345,000,000 | $301,000,000 | $81,000,000 |
| Operating Income | $13,327,000,000 | $10,251,000,000 | $8,722,000,000 | $4,512,000,000 |
| Gross Profit | $48,106,000,000 | $43,866,000,000 | $37,543,000,000 | $31,960,000,000 |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $6.54 | $4.50 | $3.81 | $2.11 |
| Basic EPS | $6.60 | $4.54 | $3.84 | $2.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $66,060,000 | $-29,047,290 | $-66,485,288 | $-140,790,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $19,139,000,000 | $15,591,000,000 | $13,911,000,000 | $9,826,000,000 |
| Total Unusual Items | $367,000,000 | $-153,000,000 | $-489,000,000 | $-741,000,000 |
| Total Unusual Items Excluding Goodwill | $367,000,000 | $-153,000,000 | $-489,000,000 | $-741,000,000 |
| Reconciled Depreciation | $5,490,000,000 | $5,065,000,000 | $4,934,000,000 | $5,254,000,000 |
| EBITDA (Bullshit earnings) | $19,506,000,000 | $15,438,000,000 | $13,422,000,000 | $9,085,000,000 |
| EBIT | $14,016,000,000 | $10,373,000,000 | $8,488,000,000 | $3,831,000,000 |
| Diluted Average Shares | $1,562,000,000 | $1,563,000,000 | $1,562,000,000 | $1,560,000,000 |
| Basic Average Shares | $1,550,000,000 | $1,550,000,000 | $1,549,000,000 | $1,548,000,000 |
| Diluted NI Availto Com Stockholders | $10,225,000,000 | $7,035,000,000 | $5,955,000,000 | $3,288,000,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Minority Interests | $-8,000,000 | $-6,000,000 | $-6,000,000 | $-5,000,000 |
| Tax Provision | $2,169,000,000 | $1,650,000,000 | $938,000,000 | $-792,000,000 |
| Other Special Charges | $-372,000,000 | $-12,000,000 | $9,000,000 | $573,000,000 |
| Restructuring And Mergern Acquisition | $-44,000,000 | $260,000,000 | $520,000,000 | $182,000,000 |
| Research And Development | $14,232,000,000 | $13,583,000,000 | $10,935,000,000 | $9,762,000,000 |
| Selling General And Administration | $20,774,000,000 | $20,224,000,000 | $18,222,000,000 | $17,984,000,000 |
| Impairment Of Capital Assets | - | - | - | $0 |
| Amortization | - | - | - | - |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-10,421,000,000 | $-17,416,000,000 | $-18,994,000,000 | $-22,090,000,000 |
| Total Assets | $114,074,000,000 | $104,035,000,000 | $101,119,000,000 | $96,483,000,000 |
| Total Non Current Assets | $85,351,000,000 | $78,208,000,000 | $76,065,000,000 | $73,890,000,000 |
| Non Current Prepaid Assets | $559,000,000 | $356,000,000 | $274,000,000 | $243,000,000 |
| Non Current Deferred Taxes Assets | $5,819,000,000 | $5,347,000,000 | $4,718,000,000 | $3,263,000,000 |
| Financial Assets | $498,000,000 | $182,000,000 | $228,000,000 | $74,000,000 |
| Investmentin Financial Assets | $2,223,000,000 | $1,632,000,000 | $1,530,000,000 | $1,066,000,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $11,000,000 | $0 | $0 | $10,000,000 |
| Goodwill And Other Intangible Assets | $59,088,000,000 | $58,202,000,000 | $58,137,000,000 | $59,127,000,000 |
| Other Intangible Assets | $37,846,000,000 | $37,177,000,000 | $38,089,000,000 | $39,307,000,000 |
| Current Assets | $28,723,000,000 | $25,827,000,000 | $25,054,000,000 | $22,593,000,000 |
| Hedging Assets Current | $90,000,000 | $54,000,000 | $116,000,000 | $87,000,000 |
| Restricted Cash | $22,000,000 | $129,000,000 | $102,000,000 | $162,000,000 |
| Prepaid Assets | $2,034,000,000 | $1,737,000,000 | $1,617,000,000 | $1,329,000,000 |
| Inventory | $6,557,000,000 | $5,288,000,000 | $5,424,000,000 | $4,699,000,000 |
| Other Receivables | $2,906,000,000 | $2,933,000,000 | $2,102,000,000 | $1,980,000,000 |
| Taxes Receivable | $1,158,000,000 | $1,859,000,000 | $1,426,000,000 | $731,000,000 |
| Accounts Receivable | $10,237,000,000 | $8,302,000,000 | $8,407,000,000 | $7,212,000,000 |
| Allowance For Doubtful Accounts Receivable | $-52,000,000 | $-33,000,000 | $-45,000,000 | $-59,000,000 |
| Gross Accounts Receivable | $10,289,000,000 | $8,335,000,000 | $8,452,000,000 | $7,271,000,000 |
| Cash Cash Equivalents And Short Term Investments | $5,719,000,000 | $5,525,000,000 | $5,860,000,000 | $6,243,000,000 |
| Cash And Cash Equivalents | $5,711,000,000 | $5,488,000,000 | $5,840,000,000 | $6,166,000,000 |
| Cash Equivalents | $4,379,000,000 | $4,273,000,000 | $4,515,000,000 | $4,755,000,000 |
| Cash Financial | $1,332,000,000 | $1,215,000,000 | $1,325,000,000 | $1,411,000,000 |
| Assets Held For Sale Current | - | $0 | $0 | $150,000,000 |
| Other Current Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $21,635,000,000 | $23,174,000,000 | $21,439,000,000 | $22,024,000,000 |
| Total Debt | $29,149,000,000 | $30,114,000,000 | $28,407,000,000 | $29,143,000,000 |
| Long Term Debt And Capital Lease Obligation | $26,136,000,000 | $27,619,000,000 | $23,222,000,000 | $23,690,000,000 |
| Long Term Debt | $24,715,000,000 | $26,506,000,000 | $22,365,000,000 | $22,965,000,000 |
| Current Debt And Capital Lease Obligation | $3,013,000,000 | $2,495,000,000 | $5,185,000,000 | $5,453,000,000 |
| Current Debt | $2,631,000,000 | $2,156,000,000 | $4,914,000,000 | $5,225,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $65,355,000,000 | $63,164,000,000 | $61,953,000,000 | $59,425,000,000 |
| Total Non Current Liabilities Net Minority Interest | $34,738,000,000 | $35,298,000,000 | $31,411,000,000 | $33,132,000,000 |
| Derivative Product Liabilities | $0 | $115,000,000 | $38,000,000 | $943,000,000 |
| Tradeand Other Payables Non Current | $2,939,000,000 | $1,943,000,000 | $2,617,000,000 | $3,440,000,000 |
| Non Current Deferred Taxes Liabilities | $3,500,000,000 | $3,305,000,000 | $2,844,000,000 | $2,944,000,000 |
| Current Liabilities | $30,617,000,000 | $27,866,000,000 | $30,542,000,000 | $26,293,000,000 |
| Payables | $7,501,000,000 | $8,058,000,000 | $7,623,000,000 | $5,841,000,000 |
| Other Payable | $2,017,000,000 | $2,611,000,000 | $2,280,000,000 | $1,927,000,000 |
| Total Tax Payable | $1,664,000,000 | $1,807,000,000 | $2,076,000,000 | $1,364,000,000 |
| Accounts Payable | $3,820,000,000 | $3,640,000,000 | $3,267,000,000 | $2,550,000,000 |
| Equity | ||||
| Common Stock Equity | $48,667,000,000 | $40,786,000,000 | $39,143,000,000 | $37,037,000,000 |
| Total Equity Gross Minority Interest | $48,719,000,000 | $40,871,000,000 | $39,166,000,000 | $37,058,000,000 |
| Stockholders Equity | $48,667,000,000 | $40,786,000,000 | $39,143,000,000 | $37,037,000,000 |
| Retained Earnings | $10,972,000,000 | $3,160,000,000 | $1,502,000,000 | $-574,000,000 |
| Long Term Equity Investment | $302,000,000 | $268,000,000 | $147,000,000 | $76,000,000 |
| Other | ||||
| Treasury Shares Number | $147,547 | $442,342 | $0 | $0 |
| Ordinary Shares Number | $1,550,760,380 | $1,550,103,897 | $1,550,162,626 | $1,549,800,030 |
| Share Issued | $1,550,907,927 | $1,550,546,239 | $1,550,162,626 | $1,549,800,030 |
| Tangible Book Value | $-10,421,000,000 | $-17,416,000,000 | $-18,994,000,000 | $-22,090,000,000 |
| Invested Capital | $76,013,000,000 | $69,448,000,000 | $66,422,000,000 | $65,227,000,000 |
| Working Capital | $-1,894,000,000 | $-2,039,000,000 | $-5,488,000,000 | $-3,700,000,000 |
| Capital Lease Obligations | $1,803,000,000 | $1,452,000,000 | $1,128,000,000 | $953,000,000 |
| Total Capitalization | $73,382,000,000 | $67,292,000,000 | $61,508,000,000 | $60,002,000,000 |
| Minority Interest | $52,000,000 | $85,000,000 | $23,000,000 | $21,000,000 |
| Additional Paid In Capital | $35,419,000,000 | $35,379,000,000 | $35,341,000,000 | $35,308,000,000 |
| Capital Stock | $388,000,000 | $388,000,000 | $388,000,000 | $387,000,000 |
| Common Stock | $388,000,000 | $388,000,000 | $388,000,000 | $387,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $1,105,000,000 | $1,330,000,000 | $1,520,000,000 | $1,168,000,000 |
| Non Current Accrued Expenses | $85,000,000 | $65,000,000 | $36,000,000 | $37,000,000 |
| Non Current Deferred Revenue | $55,000,000 | $0 | $7,000,000 | $14,000,000 |
| Long Term Capital Lease Obligation | $1,421,000,000 | $1,113,000,000 | $857,000,000 | $725,000,000 |
| Long Term Provisions | $918,000,000 | $921,000,000 | $1,127,000,000 | $896,000,000 |
| Current Capital Lease Obligation | $382,000,000 | $339,000,000 | $271,000,000 | $228,000,000 |
| Current Provisions | $686,000,000 | $1,269,000,000 | $1,028,000,000 | $722,000,000 |
| Defined Pension Benefit | $106,000,000 | $99,000,000 | $92,000,000 | $90,000,000 |
| Other Investments | $2,223,000,000 | $1,632,000,000 | $1,530,000,000 | - |
| Available For Sale Securities | $2,212,000,000 | $1,632,000,000 | $1,530,000,000 | $1,056,000,000 |
| Goodwill | $21,242,000,000 | $21,025,000,000 | $20,048,000,000 | $19,820,000,000 |
| Net PPE | $14,703,000,000 | $11,647,000,000 | $10,502,000,000 | $9,449,000,000 |
| Accumulated Depreciation | $-10,542,000,000 | $-8,875,000,000 | $-8,599,000,000 | $-7,743,000,000 |
| Gross PPE | $25,245,000,000 | $20,522,000,000 | $19,101,000,000 | $17,192,000,000 |
| Construction In Progress | $4,740,000,000 | $2,789,000,000 | $2,045,000,000 | $2,653,000,000 |
| Other Properties | $61,000,000 | $47,000,000 | $36,000,000 | $32,000,000 |
| Machinery Furniture Equipment | $11,156,000,000 | $9,518,000,000 | $9,199,000,000 | $7,885,000,000 |
| Buildings And Improvements | $2,048,000,000 | $1,588,000,000 | $1,352,000,000 | $1,182,000,000 |
| Land And Improvements | $7,240,000,000 | $6,580,000,000 | $6,469,000,000 | $5,440,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,923,000,000 | $1,517,000,000 | $1,568,000,000 | $1,413,000,000 |
| Work In Process | $2,777,000,000 | $2,282,000,000 | $2,325,000,000 | $1,864,000,000 |
| Raw Materials | $1,857,000,000 | $1,489,000,000 | $1,531,000,000 | $1,422,000,000 |
| Other Short Term Investments | $8,000,000 | $37,000,000 | $20,000,000 | $77,000,000 |
| Preferred Shares Number | - | - | - | - |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $8,670,000,000 | $7,275,000,000 | $6,567,000,000 | $7,237,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $14,575,000,000 | $11,861,000,000 | $10,345,000,000 | $9,808,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,905,000,000 | $-4,586,000,000 | $-3,778,000,000 | $-2,571,000,000 |
| Investing Cash Flow | $-6,808,000,000 | $-7,980,000,000 | $-4,064,000,000 | $-2,960,000,000 |
| Net Other Investing Changes | - | - | $190,000,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $-481,000,000 | $-43,000,000 | $33,000,000 | $29,000,000 |
| Financing Cash Flow | $-7,544,000,000 | $-3,996,000,000 | $-6,567,000,000 | $-6,823,000,000 |
| Net Other Financing Charges | $-70,000,000 | $-817,000,000 | $-886,000,000 | $-1,047,000,000 |
| Cash Dividends Paid | $-4,971,000,000 | $-4,629,000,000 | $-4,481,000,000 | $-4,364,000,000 |
| Common Stock Dividend Paid | $-4,971,000,000 | $-4,629,000,000 | $-4,481,000,000 | $-4,364,000,000 |
| Net Common Stock Issuance | $-481,000,000 | $-43,000,000 | $33,000,000 | $29,000,000 |
| Common Stock Issuance | $-481,000,000 | $-43,000,000 | $33,000,000 | $29,000,000 |
| Other | ||||
| Repayment Of Debt | $-2,029,000,000 | $-4,652,000,000 | $-4,942,000,000 | $-1,271,000,000 |
| Issuance Of Debt | $15,000,000 | $6,492,000,000 | $3,816,000,000 | $0 |
| End Cash Position | $5,698,000,000 | $5,429,000,000 | $5,637,000,000 | $5,983,000,000 |
| Beginning Cash Position | $5,429,000,000 | $5,637,000,000 | $5,983,000,000 | $6,038,000,000 |
| Effect Of Exchange Rate Changes | $46,000,000 | $-93,000,000 | $-60,000,000 | $-80,000,000 |
| Changes In Cash | $223,000,000 | $-115,000,000 | $-286,000,000 | $25,000,000 |
| Net Issuance Payments Of Debt | $-1,650,000,000 | $1,809,000,000 | $-965,000,000 | $-1,197,000,000 |
| Net Short Term Debt Issuance | $364,000,000 | $-31,000,000 | $161,000,000 | $74,000,000 |
| Net Long Term Debt Issuance | $-2,014,000,000 | $1,840,000,000 | $-1,126,000,000 | $-1,271,000,000 |
| Long Term Debt Payments | $-2,029,000,000 | $-4,652,000,000 | $-4,942,000,000 | $-1,271,000,000 |
| Long Term Debt Issuance | $15,000,000 | $6,492,000,000 | $3,816,000,000 | $0 |
| Interest Received Cfi | $286,000,000 | $343,000,000 | $287,000,000 | $60,000,000 |
| Net Investment Purchase And Sale | $-98,000,000 | $12,000,000 | $-7,000,000 | $-117,000,000 |
| Sale Of Investment | $131,000,000 | $108,000,000 | $129,000,000 | $42,000,000 |
| Purchase Of Investment | $-229,000,000 | $-96,000,000 | $-136,000,000 | $-159,000,000 |
| Net Business Purchase And Sale | $-1,240,000,000 | $-3,927,000,000 | $-1,179,000,000 | $-1,061,000,000 |
| Sale Of Business | $0 | $13,000,000 | $0 | $0 |
| Purchase Of Business | $-1,240,000,000 | $-3,940,000,000 | $-1,179,000,000 | $-1,061,000,000 |
| Net Intangibles Purchase And Sale | $-2,959,000,000 | $-2,539,000,000 | $-2,126,000,000 | $-1,033,000,000 |
| Sale Of Intangibles | $136,000,000 | $123,000,000 | $291,000,000 | $447,000,000 |
| Purchase Of Intangibles | $-3,095,000,000 | $-2,662,000,000 | $-2,417,000,000 | $-1,480,000,000 |
| Net PPE Purchase And Sale | $-2,797,000,000 | $-1,869,000,000 | $-1,229,000,000 | $-809,000,000 |
| Sale Of PPE | $13,000,000 | $55,000,000 | $132,000,000 | $282,000,000 |
| Purchase Of PPE | $-2,810,000,000 | $-1,924,000,000 | $-1,361,000,000 | $-1,091,000,000 |
| Taxes Refund Paid | $-2,845,000,000 | $-2,750,000,000 | $-2,366,000,000 | $-1,623,000,000 |
| Interest Paid Cfo | $-1,316,000,000 | $-1,313,000,000 | $-1,081,000,000 | $-849,000,000 |
| Change In Working Capital | $-1,137,000,000 | $-893,000,000 | $300,000,000 | $3,757,000,000 |
| Change In Payable | $1,346,000,000 | $862,000,000 | $2,394,000,000 | $1,165,000,000 |
| Change In Inventory | $-755,000,000 | $-131,000,000 | $-669,000,000 | $3,941,000,000 |
| Change In Receivables | $-1,728,000,000 | $-1,624,000,000 | $-1,425,000,000 | $-1,349,000,000 |
| Other Non Cash Items | $1,819,000,000 | $1,527,000,000 | $1,451,000,000 | $639,000,000 |
| Depreciation And Amortization | $5,490,000,000 | $5,065,000,000 | $4,934,000,000 | $5,254,000,000 |
| Amortization Cash Flow | $4,207,000,000 | $3,923,000,000 | $3,926,000,000 | $4,156,000,000 |
| Depreciation | $1,283,000,000 | $1,142,000,000 | $1,008,000,000 | $1,098,000,000 |
| Gain Loss On Investment Securities | $49,000,000 | $-95,000,000 | $-40,000,000 | $-14,000,000 |
| Net Foreign Currency Exchange Gain Loss | $31,000,000 | $42,000,000 | $34,000,000 | $16,000,000 |
| Gain Loss On Sale Of PPE | $-168,000,000 | $-64,000,000 | $-251,000,000 | $-104,000,000 |
| Net Income From Continuing Operations | $12,402,000,000 | $8,691,000,000 | $6,899,000,000 | $2,501,000,000 |
| Gain Loss On Sale Of Business | - | - | $0 | $0 |
Fetched: 2026-07-17